Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction
James R. TribbleiD, Amin Otmani, Shanshan SuniD, Sevannah A. EllisiD, Gloria CimagliaiD, Rupali VohraiD, Melissa JöeiD, Emma Lardner, Abinaya Priya VenkataramaniD, Alberto Domínguez‐VicentiD, Eirini Kokkali, Seungsoo RhoiD, Gauti JóhannessoniD, Robert W. BurgessiD, Peter G. FuerstiD, Rune BrautasetiD, Miriam KolkoiD, James E. Morgan, Jonathan Guy Crowston, Marcela VotrubaiD, Pete A. WilliamsiD
Abstract
Nicotinamide adenine dinucleotide (NAD) is a REDOX cofactor and metabolite essential for neuronal survival. Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline. Repleting NAD via dietary supplementation of nicotinamide (a precursor to NAD) is effective in preventing retinal ganglion cell neurodegeneration in mouse models. Supporting this, short-term oral nicotinamide treatment in human glaucoma patients provides a recovery of retinal ganglion cell function implying a protection of visual function. Despite this, the mechanism of neuroprotection and full effects of nicotinamide on retinal ganglion cells is unclear. Glaucoma is a complex neurodegenerative disease in which a mix of healthy, stressed, and degenerating retinal ganglion cells co-exist, and in which retinal ganglion cells display compartmentalized degeneration across their visual trajectory. Therefore, we assess the effects of nicotinamide on retinal ganglion cells in normal physiological conditions and across a range of glaucoma relevant insults. We confirm neuroprotection afforded by nicotinamide in rodent models which represent isolated ocular hypertensive, axon degenerative, and mitochondrial degenerative insults. We define a small molecular weight metabolome for the retina, optic nerve, and superior colliculus which demonstrates that ocular hypertension induces widespread metabolic disruption that can be prevented by nicotinamide. Nicotinamide provides these neuroprotective effects by increasing oxidative phosphorylation, buffering and preventing metabolic stress, and increasing mitochondrial size and motility whilst simultaneously dampening action potential firing frequency. These data support continued determination of the utility of long-term NAM treatment as a neuroprotective therapy for human glaucoma. One Sentence SummaryThe NAD precursor nicotinamide has a potent neuroprotective effect in the retina and optic nerve, targeting neuronal function, metabolism, and mitochondrial function.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 221
- FWCI
- 30.90
- Field percentile
- top 1%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protective effects of nicotinamide in a mouse model of glaucoma DBA/2 studied by second-harmonic generation microscopy
Vinessia Boodram, Hyungsik Lim·bioRxiv·Mar 7, 2024
- The 5-HT1A receptor antagonist WAY-100635 maleate reprograms metabolism to promote RGC differentiation and regeneration in retino-visual centers
Sayanta Dutta, Michelle L. Surma, … Arupratan Das·Communications MedicinePeer-reviewed·Apr 2, 2026
- Oral supplementation with Nicotinamide Riboside treatment protects RGCs in DBA/2J mouse model
Nan Zhang, Ying Li, … Jeffrey H. Boatright·bioRxiv·Dec 3, 2024
- Genetic and pharmacological correction of impaired mitophagy in retinal ganglion cells rescues glaucomatous neurodegeneration
Prabhavathi Maddineni, Bindu Kodati, … Gulab S Zode·bioRxiv·Feb 13, 2025
- Oral administration of a dual ETA/ETB receptor antagonist promotes neuroprotection in a rodent model of glaucoma
Nolan R. McGrady, Dorota L. Stankowska, … Raghu R. Krishnamoorthy·bioRxiv·Oct 27, 2020
- Oral pyruvate prevents glaucomatous neurodegeneration
Pete A. Williams, Jeffrey M. Harder, … Simon W. M. John·bioRxiv·May 2, 2020